Background. High rates of persistence of human papillomavirus (HPV) infection have been reported for adult women with human immunodeficiency virus (HIV) infection. Although most women are first infected with HPV during adolescence, persistence of specific HPV types has not been carefully examined among HIV-infected adolescents. The objective of this study was to examine the rates of and risk factors for persistence of HPV types among HIV-infected and -uninfected adolescent girls.
precancer even as adolescents [2] [3] [4] [5] . Although factors that influence persistence of HPV are not yet well understood, several studies suggest that alterations in cellmediated immune responses play a large role in persistence of HPV.
The higher rates of HPV infection, high-grade squamous intraepithelial lesion (HSIL), and cervical cancer among immunosuppressed individuals, specifically HIV-infected women, underscore the importance of immune control in HPV infection. Studies of adult women have consistently shown that the prevalences of HPV infection and HSIL are greater among HIVinfected women and that these differences are exaggerated among women with lower CD4
+ cell counts [6] [7] [8] . Other studies, including our previous study of adolescents, have found that differences in prevalence are associated with HIV status even among those with normal CD4 + cell counts, suggesting that factors other than CD4 immunosuppression, as reflected by CD4 + cell counts, affect persistence of HPV [8, 9] . The in-terpretation of the results of these prevalence studies is limited, since high rates of HPV acquisition among HIV-infected women may, in part, explain these differences [10] . Several recent prospective studies have documented that the rate of persistence of HPV among HIV-infected women is higher than that among HIV-uninfected women [10] [11] [12] . HPV genotypes most likely play a role in immune evasion, since certain HPV types (such as type 16) are more likely to persist than are other HPV types [13] . Advancements in DNA sequencing have added to our understanding of HPV genetics. Phylogenetic trees based on DNA homology have been constructed for HPV grouping by similar, or like, types [14] . Immunologic responses to similar types may give us insight into antigen recognition.
Studies of incident infections show that the majority of women acquire HPV shortly after the initiation of sexual activity [15, 16] and that the majority of these infections are transient, with 5%-10% resulting in persistence. Since the detection of HPV in older adult women (130 years) most likely reflects an existing persistent infection, the study of early HPV infection is best suited to adolescent populations, since adolescents have had fewer years of sexual activity, in comparison with adults. The objectives of this study were to compare rates of persistence of phylogenetically similar high-risk and low-risk HPV types among HIV-infected and -uninfected adolescent girls and to examine immunologic, biologic, and behavioral risk factors associated with persistence of HPV.
SUBJECTS AND METHODS

Subject population.
The Reaching for Excellence in Adolescent Care and Health (REACH) project of the Adolescent Medicine HIV/AIDS Research Network recruited HIV-infected and high-risk HIV-uninfected adolescents, aged 13-18 years, into a study of biomedical and behavioral characteristics associated with HIV infection, as seen in primary care practices at 15 different clinical sites in 13 US cities. Characteristics of the cohort, recruitment and eligibility criteria, and study design are reported in detail elsewhere [17] . In brief, the study enrolled eligible adolescents who were under medical care and who had acquired HIV infection through sexual activity or injection drug use, the latter of which was rarely reported in our cohort ( ). The study also recruited HIV-uninfected girls and n p 2 boys, in a preplanned ratio of 2:1 (HIV infected:HIV uninfected), who were of comparable age and who had reported high-risk behaviors (i.e., sexual activity and illegal substance abuse). This study only reports results for the girls. Informed consent was obtained from all subjects or their parents or guardians, and human experimentation guidelines of the US Department of Health and Human Services and those of the Institutional Review Boards of the authors' institutions were followed in the conduct of clinical research. Seroconversion was not observed in the girls.
Data were obtained through face-to-face interviews, review of medical charts, and audio computer-assisted systematic interviews [18] . The protocol required that this information be collected at baseline and at 6-month intervals. Results of examinations at baseline and at 6-month intervals have been described elsewhere [9] . Specific to this study were analyses of vaginal samples for evidence of bacterial vaginosis, using Gramstain criteria [19] , and of Trichomonas vaginalis infection, using wet mount or culture; a cervical sample obtained by use of a Weck-Cel sponge (Xomed Surgical Products), for cytokine measurements; a 10-mL cervical vaginal lavage for testing for HPV infection; and an endocervical sample for testing for Chlamydia trachomatis and Neisseria gonorrhoeae infection. After the application of 5% acetic acid, a picture of the cervix was obtained by means of a cerviscope (Cervigram, National Testing Laboratories), for documentation of percent ectopy [20] . Blood samples then were obtained for testing for cytomegalovirus (CMV) and herpes simplex virus (HSV) infection and for CD4 + and CD8 + T cell counts, cytokine measurements, and flow cytometry. Blood samples for CD4 + and CD8 + cell counts were obtained at 3-month intervals, and blood samples for the expanded flow-cytometry panel (see below) were obtained at 6-month intervals.
Quantitative immunophenotyping of CD4 + cell counts was determined at the individual clinical sites in certified laboratories using AIDS Clinical Trials Group standardized flow-cytometry protocols. Plasma HIV loads were tested at a central laboratory using Nucleic Acid Sequence-Based Amplification (Organon Technika) until NucliSens (Organon Technika) became available [21, 22] . Assays in the expanded flow-cytometry panel included CD8 + /CD38 + , a marker associated with HIV progression. The flow cytometry for CD8 + /CD38
+ was performed at a central laboratory, as described elsewhere for the REACH cohort [23, 24] .
The control of HPV infection has been thought to be mediated primarily through host cell-mediated immune responses. HIV infection certainly affects immune responses through the depletion of CD4 + cells. However, other immune responses are thought to be affected, including cytokine responses measured in both the peripheral blood and mucosal tissue. Consequently, we examined the association between persistence of HPV and cytokine levels in peripheral blood and cervical mucous. Measurements of simulated interferon, interleukin (IL)-2, IL-4, IL-6, and tumor necrosis factor were done with peripheral blood mononuclear cells, at the central immunology laboratory [25] . Samples of cervical mucous were obtained by use of Weck-Cel sponges, for measurement of IL-10, IL-12, and IL-2 [26] [27] [28] .
HPV testing. Cervical vaginal lavage samples were processed at the central laboratory by use of polymerase chain reaction (PCR) amplification, as described in detail elsewhere [9] . Samples were amplified by use of the consensus primers MY09/11 and HMB01 and were probed for a consensus probe [9] and for 30 different HPV types, by use of a chemiluminescent dot-blot format. The HPV types are listed in table 1. PCR data were classified as follows: negative; positive for the specific types identified; or "positive, type unknown" if the sample was positive with the generic probe but did not hybridize to any of the specific probes. Samples negative for bglobin were considered to be inadequate and were excluded from analysis. Baseline serum samples for serologic testing of HSV-2 were sent to the laboratory of Dr. Scott Schmid at the Centers for Disease Control and Prevention (Atlanta), for processing using a gG-based type-specific serologic assay [29] . Serum samples for serologic testing of CMV (referenced as positive or negative) were sent to local hospital laboratories near the clinical sites.
Statistical considerations.
This observational longitudinal study involved repeated measurement, onset and loss of infection, and both fixed and time-varying covariates. HPV infection was either present at baseline (prevalent) or absent at baseline but detected at a 6-month study visit (incident). Time to incident infection was defined as baseline to time of detection of HPV.
Time to loss of HPV infection was defined as time from initial identification of HPV infection, whether at baseline or during study, to time of the first of 2 consecutive negative test results. A negative test result was defined as the loss of infection with the initial HPV types, irrespective of later incident infection with other types. We compared loss of infection defined by 1 negative test result with that defined by 2 consecutive negative test results: the more stringent definition (2 consecutive negative test results) had a mean time to clearance of 259 days more than that for a single negative test result. We chose the stringent definition of 2 consecutive negative test results, given the variability of HPV detection using PCR [2, 10, 12, 30] .
HPV infection was classified into subgroups based on the phylogenetic patterns of high-risk HPV types 16-like, 18-like, and 56-like and of HPV types rarely, if ever, associated with a cancer diagnosis (i.e., low-risk types) [14] . Although the literature is somewhat confusing with regard to the phylogenetic groupings of HPV types 51 and 26, we based these groupings on published nucleotide alignments (HPV Sequence Database, Los Alamos National Laboratory). Table 1 gives the definitions for the phylogenetic categories and their frequencies in the cohort. Because of coinfections between categories, some patients were classified into 11 subgroup, and the subgroups were not mutually exclusive. The analytic approaches used consider this issue. We note that the groupings are a combination of clades. Kaplan-Meier and multivariate Cox proportional hazards (PH) methods were used to analyze both time to onset and to loss of HPV infection [31, 32] . We used PROC LIFETEST (SAS Institute) for the Kaplan-Meier analysis and PROC PHREG (SAS Institute) with time-dependent covariates for PH regression analysis, and best-subset selection was determined by means of the x 2 statistic for assessing models [33] . Differences among nonparametric estimates of survival curves [31] were assessed using Wilcoxon and log-rank (which is more sensitive to differences occurring later in time) tests for time-to-event univariate analysis. The x 2 test was used for contingency-table evaluations of differences in categorical outcomes. The continuity correction was used for tables, and Fisher's exact 2 ϫ 2 test was used as required.
More prevalent cases of HPV infection were associated with HIV-infected subjects than were incident cases of HPV infection (71.3% vs. 47.8%, respectively; ). A difference P p .0002 in mean time to loss of HPV infection was found among subjects with incident infection, versus subjects with prevalent infection (589 days vs. 1046 days, respectively; ), al-P ! .0001 though the differences in proportion of loss of HPV infection were not statistically significant (49.3% vs. 37.8%, respectively; , Fisher's exact test). A univariate Cox regression analysis P p .09 of the interaction of time with time of onset of HPV infection (prevalent vs. incident) with clearance was statistically significant, indicating that the assumption of PH for this variable does not hold. On the basis of these considerations, the approach to analysis was to stratify by prevalent or incident infection status in the multivariate analyses. The estimates of the hazard ratios are adjusted for the covariates shown in the PH models and for the time of onset of HPV infection as a stratification variable (prevalent or incident). When data for CD4 + cell counts were missing between 2 known values, the missing data were computed as the mean of the 2 adjacent values.
Univariate PH regression was used to reduce the number of potential predictors of clearance (predictors considered are given in the note to table 3). A subset of predictors (those with or with strong external evidence) was considered in the P ! .05 multivariate analysis for all subjects and for HIV-infected subjects only. Adjustments for multiple comparisons were not used, to avoid missing the chance of observing clinically important associations [34] . Interaction terms were introduced on the basis of results of prior studies reported in the literature or initial analyses.
RESULTS
Description of subjects. Data were available for 411 girls in the REACH project master data file as of March 2001. The primary longitudinal analysis on incidence and persistence relied on data from a subset of these subjects, selected on the basis of the study inclusion criteria. Of these 411 adolescent girls, 334 (222 HIV infected and 112 HIV uninfected) met the inclusion criteria for the persistence study; 31 subjects (7.5%) were excluded because they had р1 adequate (i.e., positive for b-globin) HPV test result, and additional subjects were excluded because they were not HPV infected during the study (31 subjects [7.5%]) or because they had inadequate followup (i.e., !2 visits) after diagnosis of HPV infection (15 subjects [3.6%]). REACH study visits were scheduled for HPV testing every 6 months, and the mean number of visits was 6.03 for HIV-infected subjects and 5.54 for HIV-uninfected subjects ( , Kruskal-Wallis test). Approximately 91% of sched-P p .06 uled visits for HPV testing were completed.
Distribution of HPV types is given in table 1, by HIV status of subjects. Infection with multiple subgroup types was common in this population, with 51% of HIV-infected and 30% of HIV-uninfected adolescents having infection with 11 risk group (low-risk, 16-like, 18-like, or 56-like). Infection with multiple high-risk HPV subgroups was also common, with 40.7% of HIV-infected subjects having infection with 11 highrisk subgroup type (16-like, 18-like, or 56-like). In comparison, 22% of the HIV-uninfected girls had infection with multiple high-risk subgroup types ( ). P p .0026 The demographic characteristics of the 334 subjects used for this analysis are given in table 2, by HIV status of subjects. Overall, the HIV-infected group had higher-risk sexual behavior at baseline, including younger age at first vaginal intercourse and greater number of sex partners during lifetime.
At time of enrollment, 125 subjects (61 HIV infected and 64 HIV uninfected) entered the REACH project with no HPV infection. During the study, the difference in mean time to first HPV infection for HIV-infected and -uninfected subjects was not statistically significant (518 days [SE, 42.2 days] vs. 517 days [SE, 48.2 days], respectively). For both groups combined, the 2-year incidence of HPV infection was 62.0%. The incidence by the end of follow-up was 67%.
Loss of HPV infection. The first analysis examined the time to clearance of initial HPV types identified ( figure 1) . Among HIV-infected subjects, 59.0% had HPV clearance of all initial HPV types, and 75.9% of the HIV-uninfected subjects had clearance by end of follow-up. Time to clearance was longer among the HIV-infected adolescents, with a mean time to loss of infection with initial HPV types during the study of 689 days (SE, 33.5 days) for HIV-infected subjects and 403 days (SE, 33.9 days) for HIV-uninfected subjects ( ).
The clearance of infection with each of the high-risk HPV types was examined next. The estimated survival curves for time to clearance for each of the 3 high-risk HPV subtypes (16-like, 18-like, and 56-like) are shown in figure 2 for HIVinfected (top panel) and HIV-uninfected (bottom panel) subjects. The estimated survival curves for the 3 HPV phylogenetic groups (regardless of coinfection with other high-risk types) are shown separately for HIV-infected and -uninfected subjects. The comparisons of the estimated survival curves for each initial infection type all show differences in clearance times for HIV-infected versus -uninfected subjects. The mean times to loss of HPV infection for HIV-infected versus -uninfected subjects, respectively, are as follows: for HPV type 16-like, 849 days (SE, 44.4 days) versus 468 days (SE, 41.5 days); for HPV type 18-like, 826 days (SE, 58.7 days) versus 457 days (SE, 45.5 days); and, for HPV type 56-like, 882 days (SE, 63.5 days) versus 424 days (SE, 67.3 days). Although the comparison of clearance profiles by initial infection types among the HIV-infected or -uninfected subjects is confounded by the overlap of subjects among the groupings, the clearance patterns across initial infection types are similar. When survival curves for mutually exclusive groups with infection by high-risk HPV types 16-like only, 18-like only, and 56-like only were compared, no statistical differences were found. The multivariate analysis that follows considers mutually exclusive groups of subjects with initial infection by high-risk HPV types.
Multivariate analysis for loss of HPV infection. Variables considered for multivariate PH analysis included HIV infection status; HPV infection status (HPV type, single or coinfection); CD4
+ cell counts; cervical IL-10, IL-12, and IL-2 concentra- ) were considered, multivariate regression showed that HIV status was highly significant (P p ) as an independent predictor (HR, 1.60; ). .012 P p .012
DISCUSSION
Studies of adult women have shown that HPV infection with both high-risk and low-risk HPV types is more likely to persist among HIV-infected women [10, 11, 35] . Our findings show that the natural history of HPV infection is influenced by HIVinfection status even during the early stages of HIV infection. Because they have more years of sexual activity, adult women may reflect a group of women further along in their history of HIV and HPV infection. This comparison is supported by the fact that our group of adolescents appeared to be healthier than the adult women in previous studies, since few of these adolescents had a CD4 + cell count !200 cells/mm 3 at study entry, despite the fact that the majority were not undergoing therapy.
When we examined the association between HPV clearance The survival curves were found to be statistically different by use of the Wilcoxon test ( ) and log-rank test ( ). Study visits were P ! .0001 P ! .0001 scheduled at 6-month intervals. and HIV status more closely, clearance times were longer among the HIV-infected subjects for all the HPV phylogenetic categories examined. We were limited in commenting on low-risk HPV types because these types were almost always found in conjunction with high-risk HPV subgroups (data not shown).
Interestingly, the prevalence of infection with low-risk HPV types among our adolescents was lower than that reported in studies of adults. The increased persistence of HPV among the HIV-infected adolescents did not appear to be related to differences in rates of acquisition of HPV, since the incidence of infection was similar among HIV-infected and -uninfected adolescents. The high rate of acquisition reported here is similar to that reported for populations of adolescents and young women in general [16] and is not surprising given the high rates of new sex partners.
The role of HIV infection in the persistence of HPV most likely is complex. We found that the presence of HPV types from multiple HPV subgroups and low CD4 + cell count appear to play important but independent roles in persistence of HPV. The presence of multiple HPV subgroups may reflect a dysfunction in the immune response that is not indicated by CD4 + cell counts and that has been occurring for an extended period of time-that is, whenever an HIV-infected person acquires a new HPV type, that HPV type is more likely to persist. If the HIV-infected individual remains sexually active and continues to acquire new HPV types, the chance that 11 HPV type will be present at any time will be greater than that for HIV-uninfected girls who rapidly clear HPV after each infection. Some have argued that the presence of multiple HPV types in an HIV-infected person is explained by the reappearance of HPV types that were latent, versus acquisition of new types. An alternative theory may be that multiple HPV infections may have some mutual cobenefit for the survival of HPV.
Our data continue to support the important role of CD4 + cells [10, 35] in the control of HPV infection: the lower the CD4 + cell count, the more likely that HPV infections will persist. In the multivariate regression analysis, although HIV status was borderline significant as a predictor independent of CD4 + cell count, HIV status was highly significant ( ) for the P p .012 cohort with normal CD4 + cell counts (i.e., у500 cells/mm 3 ). NOTE. Predictor variables considered in the univariate analysis included fixed and time-dependent covariates. Variables that were fixed (i.e., measured only at baseline) included HIV status, infection with single vs. multiple highrisk HPV types (coinfection), age at first vaginal intercourse, age of subject at baseline, race, and laboratory-confirmed herpes simplex virus type 2 and cytomegalovirus (CMV) infection at baseline. Time-dependent variables measured at each study visit included CD4 + T cell counts measured continuously; smoking; percent ectopy; laboratory-confirmed cervical gonorrhea, chlamydia, or trichomoniasis; bacterial vaginosis; CMV seroconversion; vaginal yeast infection; levels of peripheral blood-stimulated cytokine proteins interferon, interleukin (IL)-2, IL-4, IL-6, and tumor necrosis factor; peripheral blood CD8 + /CD38 + cell count; IL-10, IL-12, and IL-2 concentrations and ratios in cervical secretions; abstinence from sexual intercourse in the 3 months prior to a study visit; current pregnancy; external genital warts; marijuana use; other illicit drug use ( This finding suggests that HIV may interact with HPV in ways not limited to CD4 immunosuppression. In a previous publication [26] , we showed that, in the cervical mucous, HIVinfected women had altered cytokine responses to HPV infection, compared with the responses in HIV-uninfected women. When infected with HPV, HIV-infected women had levels of IL-10 that were 6-fold higher than those in HIV-uninfected women with HPV infection. Although univariate associations with IL-10 levels were found in this prospective analysis, the multivariate analysis showed no correlation with persistence of HPV for any of the subgroup types. The lack of association may be due to timing of sample collection, since measurement of the cytokine levels may not reflect the cytokine expression at the time of the loss of infection, if the loss occurred between the 6-month visits.
The finding that marijuana use was positively associated with HPV clearance is interesting. Whether this association is a direct biologic effect or an indirect effect of some other behavior is not clear. Data from a previous analysis of this cohort [36] suggest that marijuana use increases NK cell activity, which may play a role in HPV control [37] . The role of NK cell activity was not examined in this study but may be an interesting focus for future studies.
Comparison of our data with that for adults is difficult, since many of the studies of adults did not group results by phylogenetic types and had limited times of observation. In the only study to examine phylogenetic types, Sun et al. [11] reported that 14% of HIV-infected women, compared with 3% of HIV-uninfected women, had persistence of HPV type 16-like and 8% of HIV-infected women and none of the HIVuninfected women had persistence of HPV type 18-like. The lower rate of persistence in that study probably is due to at least 3 factors. First, the researchers used a less stringent definition of persistence, requiring the detection of the same HPV type at only у2 examinations during a period of 3-12 months. We observed in the present study that the definition of loss of infection was quite different if the criteria required 1 negative or 2 consecutive negative test results. Several studies have shown that detection of HPV can fluctuate for reasons not well understood [10, 11, 30] . Second, the number of different HPV types identified within each group was greater in our study, compared with that of Sun et al. We had identified 6 HPV types in the HPV type 16-like category and 9 in the HPV type 18-like category, compared with 5 and 2 types, respectively, identified in the study by Sun et al. Third, Sun et al. excluded all women with squamous intraepithelial lesion (SIL) at baseline, influencing rates of persistence, since women with untreated SIL are expected to have higher rates of persistence than women without SIL. On the other hand, excluding subjects with SIL excludes individuals with known HPV infection and does not necessarily result in exclusion of all cases of SIL, since cytologic testing is relatively insensitive.
A study by Ahdieh et al. [10] was more similar to our study than was the study by Sun et al. [11] , because women with SIL were not excluded and the observation period was longer. However, there were important differences. First, the average age of the subjects was 130 years. Second, the oncogenic categories of HPV risk were not strictly comparable to our phylogenetic categories of HPV risk, and these categories were defined so that subjects with multiple high-risk HPV types were assigned to the category of the highest-risk type, eliminating the possibility of demonstrating the importance of concurrent infection with multiple HPV types (as shown in table 3). Finally, the multivariate analyses were performed for subjects with and those without HIV infection, in contrast to our approach using HIV status as a covariate in the multivariate model. In spite of these differences in approach, Ahdieh et al. [10] reported the importance of CD4 + cell count and observed similar rates of persistence, with 45% of HIV-infected women having persistence of the same HPV type at 36 months after infection, compared with only 15% of the HIV-uninfected women. They also showed that no differences in persistence were found by their categories of HPV risk (high, intermediate, and low) among either HIV-infected or -uninfected women. We acknowledge that the phylogenetic categories we created may not have clinical relevance; however, the HPV types 16-like, 18-like, and 56-like were predominantly made up of high-and intermediate-risk types (table 1). Our findings compliment those of Ahdieh et al. by showing no association of HPV clearance with phylogenetic HPV types and a negative association with infection by multiple high-risk types.
In conclusion, HIV-infected adolescents were at risk for persistence of high-risk HPV types. In addition to HIV status, predictors of persistence of HPV included CD4 immunosuppression and presence of multiple HPV-type subgroups. Since persistence of high-risk HPV types has been strongly linked with the development of invasive cancer, the prolonged persistence of HPV observed in HIV-infected adolescents who are relatively healthy underscores the importance of prevention of HPV infection. Vaccine trials for prevention of HPV infection should be targeted for HIV-infected adolescents.
